Moderna has been searching for new applications for mRNA, which facilitated fast development and production of COVID-19 vaccines. The company has now developed a personalized skin cancer vaccine, which in combination with Merck's Keytruda medication has reduced death from melanoma or reoccurrence of the skin cancer by 44% in studies. 

Read Full Story